Nicotine Science and Policy
By Harry Shapiro Aug. 13, 2026
Harry's blog 134: Filtering out lies and misinformation
The only major global journal focused on harm reduction has gone bust. Since 2017, Filter has advocated through journalism for rational and compassionate approaches to drug use, drug policy and human rights, while also standing out for its coverage of tobacco harm reduction. Its closure is a significant loss - particularly at a time when well-funded opponents of tobacco harm reduction continue to thrive.
October 13, 2026 by brusselstimes.com
Brussels is funding the voices that tell it what it wants to hear
Brussels’ nicotine debate has a transparency problem when public money funds organisations that then echo the Commission’s preferred line. The article points to a “market freeze” backed by several health ministers that would restrict future nicotine products while cigarettes remain available. That should concern anyone interested in evidence-based regulation. Public health policy needs independent scrutiny, consumer voices and open funding trails — especially when decisions could limit lower-risk alternatives for millions of adults who smoke.
21.70% of the adult population are current smokers. There are approximately 2.1 million current smokers in Belgium 24.70% of men are current smokers but only 18.90% of women.
SOURCE: GSTHR
October 13, 2026 by daily-pouch.com
Media Watch: The WSJ Suggests Wellness Types Are Rehabilitating Nicotine
Nicotine entering wellness culture creates a communication challenge public health cannot ignore. A product may be smoke-free and far less harmful than cigarettes, but that does not make nicotine a lifestyle supplement or a harmless productivity tool. The clearest message is also the most nuanced: non-combustible nicotine can matter for smokers moving away from combustion, while non-users should not be encouraged to start. Risk communication needs to hold both truths at once.
October 13, 2026 by clearingtheair.eu
UK smoking falls below one in 10 ahead of nicotine pouch age restrictions
The UK’s smoking rate falling below one in ten is a milestone worth protecting. It has happened alongside wider use of smoke-free nicotine products, which makes upcoming pouch restrictions especially important to get right. Age limits can help prevent youth access, but they should not blur the role pouches may play for adults looking for alternatives to cigarettes. The next phase of UK policy should keep the focus on the outcome that matters most: fewer people smoking.
11.80% of the adult population are current smokers. There are approximately 6.7 million current smokers in United Kingdom 13.60% of men are current smokers but only 10.10% of women.
SOURCE: GSTHR
October 13, 2026 by weareinnovation.global
Eight EU Capitals Want to Ban Products That Don’t Exist Yet
Banning products before they even exist is not precaution; it is policy closing its eyes to innovation. Eight EU capitals pushing restrictions on future nicotine products risk freezing the market around what already exists, including cigarettes. New products should face evidence, standards and scrutiny, not pre-emptive exclusion based on category fear. A smarter European approach would regulate risk as it emerges, while keeping the door open to technologies that could help move smokers further away from combustion.
October 13, 2026 by planetofthevapes.co.uk
Vape Tax Needs Watching
Vape tax needs watching because small price changes can become big behaviour changes. For adults who have switched from smoking, affordability can help keep the lower-risk option within reach; for those still smoking, it can influence whether switching feels realistic at all. A poorly calibrated tax may push people back towards cigarettes or towards cheaper illicit products. The test should be simple: does the policy keep movement away from combustion attractive, or does it make that progress harder to sustain?
11.80% of the adult population are current smokers. There are approximately 6.7 million current smokers in United Kingdom 13.60% of men are current smokers but only 10.10% of women.
SOURCE: GSTHR
- Page 1 of 46
Blogs
Harry's blog 134: Filtering out lies and misinformation
The only major global journal focused on harm reduction has gone bust. Since 2017, Filter has advocated through journalism for rational and compassionate approaches to drug use, drug policy and human rights, while also standing out for its coverage of tobacco harm reduction. Its closure is a significant loss - particularly at a time when well-funded opponents of tobacco harm reduction continue to thrive.
Harry’s blog 133: Silence is consent
Two tobacco control consultations that demand your attention
I’m sure there are many of you like me who are deeply cynical about public consultations. They often feel like political tick box exercises allowing the issuing authority from local councils to international organisations to say they have ‘consulted with the people’, when in truth they knew exactly what they were going to do from the get-go.
Harry’s Blog 132: “Zyn! Went The Strings Of My Heart” (with apologies to Judy Garland)
FDA approval of 20 nicotine pouch products is another step forward for tobacco harm reduction
The FDA in the U.S. has granted marketing authorisation for Zyn nicotine pouch products (five variations on mint plus five other flavours in two different strengths).
In its letter to PMI (who own Zyn manufacturers Swedish Match), the FDA wrote:
Based on our review of your MRTPAs [Modified Risk Tobacco Applications] we determined that the proposed modified risk tobacco products, …as actually used by consumers would significantly reduce harm and the risk of tobacco-related disease to individual tobacco users and benefit the health of the population as a whole, taking into account both users of tobacco products and persons who do not currently use tobacco products. Therefore, we authorize marketing of the tobacco products as modified risk tobacco products with the following modified risk information – “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis”.